Disease Landscape and Forecast Insights

Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of several combination regimens that include BRAF and MEK inhibitors, as…

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung cancer (NSCLC), highlighting the importance of biomarker-driven…

The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to…

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure (CHF) cases. Our understanding of the pathophysiology of the disease has improved…

MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage…

DRG Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

September 2019Physicians treating renal anemia are limited to iron supplements and erythropoiesis-stimulating agents (ESAs), which, although effective, have significant drawbacks. The hypoxia-…

Treatment of recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens…

Triple-negative breast cancer (TNBC) is a patient population with high unmet need given the poor outcomes associated with current treatment options and the historic lack of targeted therapies…

Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is severely undertreated. The failure of therapies to improve walking distance or reduce…

MARKET OUTLOOK NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of…

MARKET OUTLOOK Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years. Owing to the lack of rapid diagnostics, the…